NPHS2

Across TCGA pan-cancer cohorts, NPHS2 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated NPHS2 data layer compared with 4 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher NPHS2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated NPHS2 expression acts as an unfavorable survival marker, although some lineages such as READ and HNSC show a favorable association.

LIHC, THCA, and LUAD are the cancer types where NPHS2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.490	0.727	<.001	105	view →
THCA	DFS	Tertile	III,IV	0.493	0.843	<.001	81	view →
LUAD	OS	Tertile	III,IV	0.433	0.701	.014	39	view →
ESCA	OS	Tertile	All	0.489	1.000	<.001	39	view →
CESC	OS	Tertile	IV	0.121	0.591	.029	36	view →
KIRP	OS	Quartile	All	0.553	0.840	<.001	31	view →
READ	OS	Median	All	1.000	0.869	.008	27	view →
HNSC	OS	Tertile	II,III,IV	0.536	0.354	.022	24	view →
DLBC	DFS	Tertile	III,IV	0.137	0.761	.014	21	view →
UVM	OS	Tertile	All	0.586	0.878	.022	18	view →
UCEC	DFS	Tertile	All	0.867	0.904	.025	18	view →
BLCA	DFS	Median	III,IV	0.170	0.424	.003	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

NPHS2–LIHC (OS)

Open the LIHC breakdown →